Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for Thrombocytopenia in Low- and Intermediate-Risk MDS
NCT02912208Phase 2Active, not recruiting
- Sponsor
- Qol-one
- Start
- Jun 2011
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of eltrombopag in Thrombocytopenia, sponsored by Qol-one. Started Jun 2011; status: active, not recruiting.
02
Drugs
eltrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT02912208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912208.